The development of various cancers, such as breast cancer (Shimo et al., 2007), lung adenocarcinoma (Zhan et al., 2017) and pancreatic cancer (Nakamura et al., 2004), was associated with the overexpression of PRC1. Meanwhile, the dysregulation of PRC1 was demonstrated to be related to the early recurrence and chemoresistance of HCC (Chen et al., 2016; Wang et al., 2017). Here, PRC1 is linked to pancreatic neoplasm.